We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Research compound — not a dietary supplement
Ephedrine is a research compound, not a regulated dietary supplement. It is sold for research or off-label use. The evidence below is largely preclinical (animal and in-vitro) or early-stage, so no evidence score is assigned. This page is provided for transparency and education — it is not a recommendation to use. Consult a qualified healthcare provider, and be aware that purity, dosing, and legal status vary by jurisdiction.
What the evidence says
Most Ephedrine studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from medium-quality meta-analyses and randomised trials published 1992–2003 with a typical study size of 167 participants.
Based on 6 studies · 1 meta-analysis · 3 RCTs · 377 total participants
Confidence
ModerateBy outcome
Ephedrine has an evidence score of 3.8/10 — moderate evidence based on 6 indexed studies, including 1 meta-analysis. A sympathomimetic stimulant — the 'E' in the ECA (ephedrine/caffeine/aspirin) fat-loss stack. Ephedrine plus caffeine genuinely produces MODEST fat loss in 6-month RCTs (~0.9 kg/month more than placebo, ~3 kg over a controlled diet trial). But that is the whole upside: ephedra alkaloids were BANNED from US dietary supplements in 2004 after the FDA tied them to cardiovascular and psychiatric harms and deaths (the JAMA meta-analysis found a 2.2–3.6× increase in psychiatric/autonomic/GI symptoms and palpitations). Pharmaceutical ephedrine survives only as a restricted behind-the-counter decongestant/vasopressor. NOT a dietary supplement, NOT a longevity drug — a gated harm-reduction entry. Representative study: PMID 12672771.
The commonly studied dose of Ephedrine is Not provided as a fat-loss protocol. Ephedra-alkaloid dietary supplements are BANNED in the US, and ephedrine is a restricted behind-the-counter decongestant — not an approved weight-loss drug. For historical context only, the weight-loss RCTs used ephedrine ~20 mg with caffeine ~200 mg, three times daily under medical supervision in a research setting; this library does NOT recommend or schedule that use.. Individual needs vary — start at the lower end of the range and adjust based on how you respond.
Yohimbine
Mostly mechanism / observationalThe purified alkaloid (not crude yohimbe bark) — an alpha-2 adrenoceptor antagonist with modest evidence for erectile dysfunction and fasted fat loss, but real anxiety and cardiovascular risks and notoriously mislabeled supplement potency.
Fluoxymesterone (Halotestin)
Last reviewed June 2026 · evidence from 6 studies · how we score
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Ephedrine — sympathomimetic stimulant, the 'E' in the ECA stack
A sympathomimetic stimulant — the 'E' in the ECA (ephedrine/caffeine/aspirin) fat-loss stack. Ephedrine plus caffeine genuinely produces MODEST fat loss in 6-month RCTs (~0.9 kg/month more than placebo, ~3 kg over a controlled diet trial). But that is the whole upside: ephedra alkaloids were BANNED from US dietary supplements in 2004 after the FDA tied them to cardiovascular and psychiatric harms and deaths (the JAMA meta-analysis found a 2.2–3.6× increase in psychiatric/autonomic/GI symptoms and palpitations). Pharmaceutical ephedrine survives only as a restricted behind-the-counter decongestant/vasopressor. NOT a dietary supplement, NOT a longevity drug — a gated harm-reduction entry.
Ephedrine plus caffeine genuinely produces modest short-term fat loss in good RCTs and a JAMA meta-analysis (~0.9 kg/month over placebo), but ephedra alkaloids were BANNED from US dietary supplements in 2004 after the same evidence base tied them to a 2.2–3.6× increase in cardiovascular/psychiatric/GI adverse events plus documented strokes and deaths. Real but modest efficacy against serious, ban-triggering harms — and it is not a lawful supplement — keeps the score low.
Ephedrine is a sympathomimetic amine — historically extracted from the Ephedra (ma huang) plant and now made synthetically — that directly stimulates α- and β-adrenergic receptors and also triggers presynaptic release of noradrenaline.
The downstream effect is the classic 'fight-or-flight' profile: raised heart rate and blood pressure, bronchodilation, mild appetite suppression, and an increase in resting metabolic rate (thermogenesis).
It is famous in fitness culture as the 'E' in the ECA stack — ephedrine + caffeine + aspirin — marketed for fat loss. The honest read on efficacy: the fat-loss claim is, unusually for this category, REAL but MODEST.
In Astrup's 180-subject double-blind RCT, an ephedrine/caffeine combination beat placebo over 24 weeks on an energy-restricted diet (16.6 vs 13.2 kg lost), while ephedrine alone and caffeine alone did nothing — the synergy is the point.
Boozer's 6-month RCT of a herbal ma-huang/kola-nut combination reproduced this (-5.3 vs -2.6 kg, with body-fat and lipid improvements).
The 2003 JAMA meta-analysis (Shekelle, RAND) pooled the trials and concluded ephedrine/ephedra produces ~0.9 kg/month more weight loss than placebo — modest, short-term, with no data beyond 6 months.
Mechanistically the thermogenesis is driven by adrenergic stimulation of lipolysis and energy expenditure, potentiated by caffeine's blockade of the phosphodiesterase/adenosine brake; notably, the 'A' (aspirin) does NOT further potentiate the acute thermic response (Horton 1996), so the canonical ECA story is partly folklore.
Here is the load-bearing reason this entry scores LOW despite working: the same adrenergic drive that burns fat also raises blood pressure and heart rate and over-stimulates the central nervous system.
The same JAMA meta-analysis that confirmed the modest fat loss found a 2.2- to 3.6-fold increase in the odds of psychiatric, autonomic, and gastrointestinal symptoms and heart palpitations — that risk/benefit profile is precisely what got it banned.
Haller & Benowitz's NEJM review of 140 FDA adverse-event reports linked ephedra-alkaloid supplements to hypertension, palpitations/tachycardia, stroke, and seizures, with 10 deaths and 13 permanent disabilities among the cases judged related.
On the basis of that evidence the FDA banned ephedra-alkaloid dietary supplements in 2004 — the first dietary-supplement ingredient ever banned under DSHEA.
Pharmaceutical ephedrine itself was not banned, but it is tightly restricted: it is a precursor to methamphetamine (Combat Methamphetamine Epidemic Act sales limits), sold behind the counter as a decongestant, and used in hospitals as an injectable vasopressor for anaesthesia-induced hypotension.
It is not a lawful dietary-supplement ingredient, it is not an approved obesity drug, and it is NOT a geroprotector or longevity compound.
The honest summary: a stimulant that does produce real, modest, short-term fat loss in combination with caffeine, but whose cardiovascular and psychiatric harms — and documented deaths — drove a landmark regulatory ban. The risk is the headline, not the fat loss.
Ephedrine directly stimulates α- and β-adrenergic receptors and triggers presynaptic noradrenaline release — a sympathomimetic 'fight-or-flight' drive that raises heart rate, blood pressure, and metabolic rate. This same adrenergic stimulation is both the fat-loss mechanism and the cardiovascular-harm mechanism.
Adrenergic signalling raises resting energy expenditure and stimulates fat breakdown (lipolysis). Caffeine potentiates this by blocking the adenosine/phosphodiesterase brake on the same pathway — which is why ephedrine+caffeine works for fat loss while ephedrine alone does not. Aspirin (the 'A') does not further potentiate the acute thermic effect.
Central adrenergic stimulation reduces appetite; in mechanistic work roughly three-quarters of the weight effect of ephedrine/caffeine was attributable to reduced food intake (anorexia) and about a quarter to increased thermogenesis.
The adrenergic drive that produces thermogenesis also raises blood pressure and heart rate and over-stimulates the CNS — producing palpitations, hypertension, anxiety/psychiatric symptoms, and, in the documented adverse-event record, stroke, seizures, and deaths. This trade-off is the reason for the supplement ban.
How Ephedrine works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Tap node to isolate • Pinch to zoom • Tap edge for research
Not provided as a fat-loss protocol. Ephedra-alkaloid dietary supplements are BANNED in the US, and ephedrine is a restricted behind-the-counter decongestant — not an approved weight-loss drug. For historical context only, the weight-loss RCTs used ephedrine ~20 mg with caffeine ~200 mg, three times daily under medical supervision in a research setting; this library does NOT recommend or schedule that use.
Can be taken without food
| Form | Type |
|---|---|
| 💊None for weight loss — ephedra-alkaloid supplements are banned; pharmaceutical ephedrine is a restricted decongestant/vasopressor | Recommended |
Ephedrine is not a dietary supplement and not an approved obesity drug. The only lawful forms are the restricted behind-the-counter decongestant and the hospital injectable vasopressor.
Minimum: 1 weeks
Optimal: 1 weeks
Cycling: Not required
Note: No endorsed weight-loss timing — ephedra-alkaloid supplements are banned and ephedrine is a restricted decongestant. This library does not endorse or schedule its use for fat loss.
Dose-response data unavailable. The current published research for Ephedrine does not provide sufficient dose-specific outcome data to generate reliable dose-response curves.
Refer to the Dosage & Timing section above for recommended dose ranges based on available evidence.
Ephedrine+caffeine genuinely produces modest short-term fat loss in RCTs — roughly 0.9 kg/month more than placebo. Real, but modest, short-term, and only in combination with caffeine.
Acute increase in resting energy expenditure and a stimulant 'lift' in alertness and wakefulness from the adrenergic drive.
Raised blood pressure and heart rate, palpitations, and arrhythmia. The adverse-event record links ephedra-alkaloid products to stroke and myocardial events. This is the defining safety concern.
The JAMA meta-analysis found a 2.2–3.6× increase in psychiatric (anxiety, agitation), autonomic, and gastrointestinal symptoms — insomnia, tremor, irritability — and seizures in the case record.
Ephedra-alkaloid dietary supplements were banned by the FDA in 2004 after deaths and serious adverse events — the first ingredient banned under DSHEA. Pharmaceutical ephedrine survives only as a restricted decongestant/vasopressor.
Avoid absolutely — ephedrine raises blood pressure/heart rate and is linked to stroke and cardiac events.
Avoid — sympathomimetic stimulation worsens these and seizures appear in the adverse-event record.
Avoid — ephedrine is a stimulant banned in competition by WADA (in-competition).
Avoid entirely.
Additive sympathomimetic effect — the basis of the ECA stack, but also the basis of the cardiovascular risk: dangerous increases in heart rate and blood pressure, palpitations, and arrhythmia.
MAOIs block breakdown of catecholamines; combined with ephedrine's noradrenaline release this can precipitate a hypertensive crisis.
Tip: There is no reliable mitigation for the cardiovascular risk — raised blood pressure and heart rate are intrinsic to the mechanism. The adverse-event record includes stroke and myocardial events; combining with caffeine amplifies the risk. This is the reason ephedra-alkaloid supplements were banned.
Tip: Psychiatric and autonomic symptoms are intrinsic to the stimulant effect (2.2–3.6× more likely than placebo in the meta-analysis). Seizures appear in the case record. Avoid in anyone with anxiety or a seizure history.
Tip: Rare but catastrophic — the Haller NEJM review of 140 reports counted 10 deaths and 13 permanent disabilities. There is no mitigation other than avoidance; this is the defining concern.
The best time to take Ephedrine is in the morning. It can be taken on an empty stomach. There is no endorsed weight-loss dosing schedule — ephedra-alkaloid supplements are banned and pharmaceutical ephedrine is a restricted decongestant.
Ephedrine should be used with caution — talk to a healthcare provider before taking it. The most commonly reported side effects are hypertension / palpitations / arrhythmia, anxiety / agitation / insomnia / tremor, stroke / seizure / death (adverse-event record). Use caution if any of these apply to you: Hypertension or any cardiovascular disease — ephedrine raises blood pressure and heart rate and is linked to stroke, arrhythmia, and myocardial events; Heart arrhythmias, coronary artery disease, or history of stroke; Anxiety disorders, agitation, or psychiatric illness — sympathomimetic stimulation worsens these.
A 17α-methylated ORAL anabolic-androgenic steroid (brand Halotestin) and a DEA Schedule III controlled substance. Unlike purely veterinary or research steroids, fluoxymesterone DOES have real — if narrow and now largely historical — human prescription indications: androgen replacement in hypogonadal men, delayed puberty in boys, and palliative treatment of androgen-responsive metastatic breast cancer in women, with older use in hereditary angioedema. So there IS some genuine human clinical literature, including a randomized breast-cancer trial and case series. But it is notoriously HEPATOTOXIC: because it is 17α-alkylated, it causes cholestatic jaundice, peliosis hepatis (blood-filled liver cavities, sometimes fatal), and is linked to hepatic adenoma/carcinoma. It is strongly androgenic and virilizing, suppresses the hypothalamic-pituitary-testicular axis, and severely worsens lipids. Illicit bodybuilding use is for pre-contest strength and aggression. This is NOT a dietary supplement and NOT a longevity or performance drug this library endorses — informational, harm-reduction entry only, gated out of recommendations. The score sits low: real but narrow legacy indications cannot offset heavy hepatotoxicity and the absence of any healthy-population benefit.
Ephedrine opposes blood-pressure-lowering therapy and can destabilise rate/rhythm control.
Additive sympathomimetic and pressor effects; increased cardiovascular stimulation.